# A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration

> **NCT04643886** · PHASE2 · TERMINATED · sponsor: **Gemini Therapeutics, Inc.** · enrollment: 62 (actual)

## Conditions studied

- Dry Age-related Macular Degeneration
- Geographic Atrophy
- Macular Degeneration
- Retinal Disease
- Retinal Degeneration

## Interventions

- **DRUG:** GEM103

## Key facts

- **NCT ID:** NCT04643886
- **Lead sponsor:** Gemini Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-30
- **Primary completion:** 2022-02-18
- **Final completion:** 2022-03-21
- **Target enrollment:** 62 (ACTUAL)
- **Why stopped:** no further benefit
- **Last updated:** 2022-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04643886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04643886, "A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04643886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*